The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2023 | Session highlights: approaching patients with triple-class refractory multiple myeloma
P. Joy Ho, MBBS, FRACP, FRCPA, FFSc, The University of Sydney, Sydney, Australia, gives an overview of a session held at this year’s meeting which focused on approaching patients with triple-class refractory multiple myeloma. Several topics were addressed in this session, including how to define triple-class refractory disease and the impact of CAR-T cells and bispecific antibodies in this patient population. Prof. Ho also summarizes data from clinical trials investigating the efficacy of CAR-T cells in triple-class refractory disease, and highlights other interesting presentations that took place during this session. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
